Skip to content
FDAMedicines

UMARY- USA.COM Issues Voluntary Nationwide Recall of UNAVY ÁCIDO HIALURÓNICO Caplets and UMOVY ÁCIDO HIALURÓNICO Caplets Due to the Presence of Undeclared Drug Ingredients Dexamethasone, Diclofenac and Omeprazole

FDA recall n-umary-usacom-issues-voluntary-nationwide-recall-unavy-acido-hialuronico-caplets- ·

Build snapshot. Collected , once, when this site was built. It is not a live feed.

What the agency says to do

FDA’s record gives no instruction for consumers.

Note from Recalls Watch, not agency text

Why it was recalled

The product contains undeclared Dexamethasone, Diclofenac and Omeprazole
Text from FDA, unedited.

The recalled product

FOR IMMEDIATE RELEASE – Date: May 21 2025, Nogales, AZ, UMARY USA is voluntarily recalling all lots of Unavy Ácido HIALURÓNICO (30 caplets/850 mg) and Umovy Ácido HIALURÓNICO (30 caplets/850 mg), to the consumer level. FDA laboratory analysis confirmed that these products are tainted with the drug i
Text from FDA, unedited.

Company announcement, as FDA publishes it

FOR IMMEDIATE RELEASE – Date: May 21 2025, Nogales, AZ, UMARY USA is voluntarily recalling all lots of Unavy Ácido HIALURÓNICO (30 caplets/850 mg) and Umovy Ácido HIALURÓNICO (30 caplets/850 mg) , to the consumer level. FDA laboratory analysis confirmed that these products are tainted with the drug ingredients Diclofenac, Dexamethasone and Omeprazole . Products containing Diclofenac, Dexamethasone or Omeprazole cannot be marketed as dietary supplements. UNAVY ÁCIDO HIALURÓNICO and UMOVY ÁCIDO HIALURÓNICO are unapproved new drugs for which safety and efficacy have not been established and, therefore, subject to recall.

Risk Statement: Dexamethasone is a corticosteroid commonly used to treat inflammatory conditions. Corticosteroid use can impair a person’s ability to fight infections and can cause high blood sugar levels, muscle injuries, psychiatric problems, and lead to cardiovascular events. When corticosteroids are taken for a prolonged period, or at high doses, they can suppress the adrenal gland (a disorder in which the adrenal glands do not produce enough hormones) and adverse consequences can range from limited adverse consequences to death. Additionally, abrupt discontinuation can cause withdrawal symptoms. Diclofenac is a non-steroidal anti-inflammatory drug (commonly referred to as NSAIDs). Consumption of undeclared diclofenac could result in serious adverse events that include cardiovascular, gastrointestinal, renal, and anaphylaxis in patients taking concomitant NSAIDs and/or anticoagulants, in those who have allergies to diclofenac, or those with underlying illnesses. Omeprazole is a proton pump inhibitor (commonly referred to as PPI) used to treat gastric (stomach) acid-related disorders. Consumption of undeclared omeprazole may mask stomach issues such as erosions, ulcers, and stomach cancer. Consumption of undeclared dexamethasone, diclofenac, and omeprazole can also interact with other medications and cause serious side effects. Umary- usa.com has not received any reports of adverse events related to this recall.

These products are marketed as dietary supplements for joint pain and arthritis. UNAVY ÁCIDO HIALURÓNICO is packaged in a white plastic container with a black background label, and white and yellow writing on it. The bottle has 30 caplets/ 850 mg. The affected product includes all lots and expiration dates. UMOVY ÁCIDO HIALURÓNICO is a black plastic bottle with a black label with white and blue lettering on the label. The bottle has 30 caplets/ 850mg. The affected product includes all lots and expiration dates. Product was distributed Nationwide via internet, exclusively via umary-usa.com .

Umary-usa.com is notifying its distributors and customers by Press release and email and is arranging for return and refund of all recalled products. Consumers who have any of these products, should immediately work with their physician and/or health care provider to safely discontinue use of these products. Consumers with questions regarding this recall can contact umary-usa.com at umaryusa2025@gmail.com , available seven days a week, 24 hours a day. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Complete and submit the report Online : www.fda.gov/medwatch/report.htm1

Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm 2 or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Text from FDA (the company’s words), unedited.
  • UNAVY & UMOVY Unavy Acidio Hialuronico (30 caplets/850 mg) and Umovy Acidio Hialuronico (30 caplets/850 mg)

Source

Issued by
U.S. Food and Drug Administration
Firm
UMARY USA

Check all notices that name this firm in the directory of recalls by brand and manufacturer. This notice is in these lists: Month: May 2025, Week 2025-W21. Browse more medicines recalls, or check another notice by its number in the recall number lookup.

About this recall

What is the hazard?

FDA states: “The product contains undeclared Dexamethasone, Diclofenac and Omeprazole”

What should I do if I have this product?

FDA’s record gives no instruction for consumers. The official report is linked on this page.

Which products are included?

FDA states: “FOR IMMEDIATE RELEASE – Date: May 21 2025, Nogales, AZ, UMARY USA is voluntarily recalling all lots of Unavy Ácido HIALURÓNICO (30 caplets/850 mg) and Umovy Ácido HIALURÓNICO (30 caplets/850 mg), to the consumer level. FDA laboratory analysis confirmed that these products are tainted with the drug i”

When was this recall published?

FDA published this company announcement on May 21, 2025.